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Background. The aim of this work was to assess the value of capsule enteroscopy in the diagnosis of patients with suspected Crohn’s
Disease (CD). Methods. This was a retrospective study in a single tertiary care centre involving patients undergoing capsule
enteroscopy for suspected CD. Patients taking nonsteroidal anti inﬂammatory drugs during the thirty preceding days or with a
follow-up period of less than six months were excluded. Results. Seventy eight patients were included. The endoscopic ﬁndings
included mucosal breaks in 50%, ulcerated stenosis in 5%, and villous atrophy in 4%. The diagnosis of CD was established in 31
patients. The sensitivity, speciﬁcity, positive and negative predictive value of the endoscopic ﬁndings were 93%, 80%, 77%, and
94%, respectively. Capsule retention occurred in four patients (5%). The presence of ulcerated stenosis was signiﬁcantly more
frequent in patients with positive inﬂammatory markers. The diagnostic yield of capsule enteroscopy in patients with negative
ileoscopy was 56%, with a diagnostic acuity of 93%. Conclusions. Small bowel capsule endoscopy is a safe and valid technique for
assessing patients with suspected CD. Capsule retention is more frequent in patients with positive inﬂammatory markers. Patients
with negative ileoscopy and suspected CD should be submitted to capsule enteroscopy.
1.Introduction
The current view is that the diagnosis of Crohn’s Disease
(CD) is established by a combination, not strictly deﬁned,
of clinical presentation, endoscopic appearance, radiology,
histology, surgical ﬁndings, and, more recently, serology [1].
The role of small-bowel capsule endoscopy (SBCE) in
this context is still debateable [2], namely, because the
concept of suspected CD, with implications in the selection
of the patients, is itself under discussion. The other reason
for debate is the lack of a clear deﬁnition of the endoscopic
ﬁndings that should be considered indicative of CD. Even
though lesions such as aphthae, erosions, or ulcers may be
considered suggestive of the existence of the disease, the fact
is that other aetiologies, namely, the use of nonsteroidal anti-
inﬂammatory drugs (NSAIDs) may also be associated with
the presence of these lesions, not forgetting the fact that
healthy adults with no history of ingesting pharmaceutical
drugs may also present similar lesions [3]. Furthermore, it
is not clear whether, in the case of patients with suspected
CD, SBCE is superior to other diagnostic methods, namely,
ileoscopy [4].
The aim of this study was to assess the value of SBCE in
diagnosing CD, as well as the complications associated with
the technique.
2.MaterialandMethods
2.1.Patients. Aretrospectivestudyofpatientswithsuspected
CD who had undergone SBCE in a single tertiary care
academic centre was carried out. The criteria to perform
SBCE in our department include the absence of any clinical
or imaging study indicating the existence of stenosis of the
small intestine. The following data was collected: age, sex,
starting date of symptoms, clinical symptomatology, history
of NSAID use, examinations carried out from the onset2 Diagnostic and Therapeutic Endoscopy
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Figure 1: Jejunal ulcer.
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Figure 2: Bleeding jejunal ulcer.
of complaints to the date of SBCE, endoscopic ﬁndings,
complications associated with the examination, clinical
assessment during the follow-up period, and duration of the
same. Patents for whom there were references in the medical
ﬁles to the use of NSAIDs during the month prior to the
examinationandpatientswithafollow-upperiodoflessthan
six months after the date of the examination were excluded
from the study.
The patients were analysed according to the algorithm
proposed by the International Conference on Capsule
Endoscopy (ICCE) for suspected CD [5].
Information on patient follow-up was obtained by
contacting the referring physician. The diagnosis of CD
was established by clinical evaluation during the follow-
up period, by a combination of endoscopic, histological,
radiological, and/or biochemical investigations [1].
Erosions, ulcers, ulcerated stenosis, and villous atrophy
were considered suggestive of CD, irrespective of the number
of lesions found. Ulcers were deﬁned as white lesions within
a crater and with a surrounding erythema (Figures 1 and 2)
[6]anderosionsassuperﬁcialwhitelesionswithsurrounding
erythema (Figure 3)[ 6]. The diagnosis of ulcerated stenosis
was based on the presence of an ulcer associated with
retention of the capsule (Figure 4). The diagnosis of villous
atrophy was presumed, but not submitted to histological
conﬁrmation, after the endoscopic diagnosis of a circum-
scribed area of villous denudation (Figure 5).
2.2. Capsule Endoscopy Procedure. AP i l l C a mS B( G i v e n
Imaging Ltd; Yoqneam, Israel) was used. After an overnight
fast of 12 hours, the patients ingested the capsule with a
small amount of water with simethicone. No oral purge
was administered. All the patients were advised to drink
after four hours and, after eight hours, the sensor array
and the recording device were removed. The digital video
image streams of the examinations were downloaded to
the RAPID system. The digital image stream was assessed
and interpreted by endoscopy fellows (A.N., L.S., F.P., D.G.)
and reviewed by two staﬀ endoscopists (F.P., L.C.). The
interobserver agreement was not properly assessed, but all
the videos were widely scrutinized and discussed.
2.3. Statistical Analysis. The sensitivity, speciﬁcity, posi-
tive predictive value, negative predictive value, positive
and negative likelihood ratio of the diagnostic test, as
well as conﬁdence intervals were assessed using the Vas-
sarStats Website for Statistical Computation (available at
http://faculty.vassar.edu/lowry/VassarStats.html). Statistical
comparisons of categorical data were made using the chi-
squared test, with the Yates correction when needed, and
with the Fisher exact test. A P v a l u eo fl e s st h a n. 0 5w a sc o n -
sidered signiﬁcant. The analysis was performed with statisti-
cal software (SPSS version 11.5, SPSS Inc, Chicago, Illinois).
3. Results
Between January 2001 and December 2007, 95 patients clini-
callysuspectedofhavingCDunderwentcapsuleenteroscopy.
Fourteen of the patients were excluded from the study as it
wasstatedthattheyhadtakenNSAIDsintheprecedingthirty
days and a further three were excluded because the follow-up
period amounted to less than six months.
The demographic and clinical characteristics of the
remaining 78 patients are showed in Table 1.
With regard to previous endoscopic examinations, all
the patients had undergone colonoscopy, but no lesions
indicative of CD had been detected in any of the cases.
Retrograde ileoscopy had been carried out on 47 patients
(60.3%), revealing a slightly congested mucosa in 7 cases.
A histological study of the biopsies did not reveal any
indications of CD. In 31 patients (39.7%), the intubation of
the terminal ileum was not accomplished.
The small-bowel series revealed lesions in 5 (26.3%) of
the 19 patients who had undergone enteroclysis and in 5
(10.8%) of the 47 who had undergone small-bowel follow-
through (SBFT). A computed tomography (CT) carried out
on 37 of the patients revealed lesions in 14 cases (37.8%).
Seventy eight examinations with capsule were carried
out, achieving total enteroscopy in 64 cases (82.1%). OfDiagnostic and Therapeutic Endoscopy 3
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Figure 3: Ileal erosions.
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Figure 4: Jejunal ulcerated stenosis.
Table 1: Demographic and clinical characteristics of the patients.
Number of patients 78
Age (years) (mean ± SD) 37.2 ±16.4
Gender (female) n (%) 53 (67.9%)
Abdominal pain n (%) 62 (79.5)
Diarrhoea n (%) 47 (60.3)
Weight loss n (%) 27 (34.6)
Arthralgias n (%) 27 (34.6)
Fever n (%) 11 (14.1)
Duration of symptoms (months) (mean ± SD) 22.3 ± 26.2
Anaemia n (%) 42 (53.8)
Elevated CRP n (%) 28 (35.9)
SD: standard deviation; CRP: C-reactive protein.
the 14 cases with incomplete enteroscopy, in 4 (5.1%)
this was due to the presence of a stenosis which led to
retention of the capsule, whilst in the remaining ten cases
it was attributed to slower transit. Six of these patients with
incomplete enteroscopy, in which no lesions were detected,
were excluded from further analysis, as it was not possible
Table 2: Distribution of patients according to ICCE criteria.
N (%)
ICCE criteria present 36 (51.4)
Symptoms plus extraintestinal symptoms and signs 19 (27.1)
Symptoms plus abnormal imaging∗ 10 (16.9)
Symptoms plus inﬂammatory markers 25 (35.7)
ICCE criteria absent 34 (48.6)
Total 70
∗This group includes only the 59 patients submitted to CT or small bowel
series.
to know if they had any of the ﬁndings considered. The
remainingfourpatients,knowntopresentlesionsconsidered
suggestive of CD, were included.
No other complications, apart from retention, were
recorded.
Pathologicalimagesweredetectedin37patientsofthe72
patientsconsidered,givingthetechniqueadiagnosticyieldof
51,3%. The main endoscopic ﬁndings were mucosal breaks,
which were detected in 36 patients (50%). Five of these
patients presented ulcers, four of which were in conjunction
with erosions, whilst in one case only ulcers were found. The
remaining 31 patients presented only erosions. With regard
tothenumberofmucosalbreaks,in3patientsthisamounted
to 3 or less (4.2%) whereas in 26 cases (36.1%) it totalled 6
or more. After mucosal breaks, the most frequently detected
endoscopic ﬁndings were ulcerated stenosis, observed in 4
cases (5.5%), followed by areas of villous atrophy, observed
in 3 cases (4.2%). In 6 patients, there was more than one
type of pathological ﬁnding (3 with stenosis and mucosal
breaks, and 3 with villous atrophy and mucosal breaks).
The remaining 31 patients showed only one type of lesion,
namely, an isolated stenosis in one patient and mucosal
breaksintheremaining30(81%ofthepatientswithlesions).
We are able to evaluate ICCE criteria in 70 patients
(in two there was not enough information available in the
patient ﬁle) (Table 2). The ICCE criteria were fulﬁlled in 36
patients (51.4%). Some patients presented, in addition to
two gastrointestinal symptoms considered in the algorithm,
more than one of the following criteria: extraintestinal
manifestations, abnormal imaging studies, or inﬂammatory
markers.
Among the 36 patients with positive ICCE criteria, 20
(55.6%) presented pathological images on SBCE versus 16
(44.4%) without lesions (P = .237). In the subgroup with
inﬂammatory markers, 17 (68%) presented lesions versus
8 (32%), reaching statistical signiﬁcance (P = .022). The
presence of ulcerated stenosis was more frequent among
patients with ICCE criteria (P = .64), the diﬀerence
being statistically signiﬁcant only in the subgroup with
inﬂammatory markers (P = .014).
During the follow-up period, which lasted on average
28.8 months (sd 13.3 months) (6–65 months), 31 patients
(43%) were diagnosed with CD. The demographic and
clinical characteristics of these patients are shown in Table 3.
In relation to the four patients with ulcerated stenoses which
led to retention of the capsule, they presented symptoms4 Diagnostic and Therapeutic Endoscopy
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Figure 5: Area of villous atrophy in the ileo (arrow).
for an average of 13 months (4–24 months). Abdominal
pain, weight loss, anaemia, and elevated CRP were present
in all of them. The prior diagnostic work-up, that included
colonoscopy with retrograde ileoscopy in three, SBT in four
and CT in one, did not found any lesions. None of the four
patientsdevelopedsymptomsorsignsofintestinalocclusion.
Two patients underwent surgery involving the resection of a
segment of the small intestine, and a histological study of the
tissue showed aspects compatible with CD. The other two
patients, who were twin brothers, were only given medical
treatment and the capsule was expelled voluntarily.
Table 4 shows the sensitivity, speciﬁcity, positive predic-
tive value, negative predictive value, positive and negative
likelihoodratiooftheendoscopicﬁndings,ICCEcriteriaand
ICCE criteria plus endoscopic ﬁndings in the diagnosis of
CD.
Table 5 shows the capsule ﬁndings in patients submitted
to retrograde ileoscopy. The negative predictive value for
ileoscopy in the diagnosis of CD was 49%. It should be noted
that out of the 22 patients subsequently diagnosed with CD
in whom ileoscopy had shown no apparent lesions, in 21
cases lesions were revealed during capsule examination. The
diagnostic yield for SBCE in the 43 patients who underwent
retrograde ileoscopy was 56%, with diagnostic acuity of
93%,95%sensitivity,86%speciﬁcity,88%positivepredictive
value, and 95% negative predictive value.
4. Discussion
The sensitivity and, above all, the high negative predictive
value and low negative likelihood ratio, suggesting the high
probability of absence of the illness in patients who do
not show endoscopic lesions, are, in our opinion, the most
relevant piece of information to emerge from the study. It
is important to emphasize that the methodology used in
o u rs t u d y ,a sw i t ht h eo n er e p o r t e db yT u k e ye ta l .[ 7],
involved a follow-up period which, in our case, lasted more
than six months, extending on average to 28.8 months. The
CD diagnosis was not, therefore, established immediately on
Table 3: Demographic and clinical characteristics of the 31 patients
with conﬁrmed CD during the follow-up.
Age (years) (mean ± SD) 35.8 ± 16.2
Gender (female) n (%) 20 (64.5%)
Abdominal pain n (%) 23 (74.2)
Diarrhoea n (%) 47 (60.3)
Weight loss n (%) 17 (54.8)
Arthralgias n (%) 7 (22.6)
Fever n (%) 7 (22.6)
Duration of symptoms (months) (mean ± SD) 18.5 ± 17.2
Anaemia n (%) 20 (64.5)
Elevated CRP n (%) 16 (51.6)
ICCE criteria present n (%) 20 (68.9)
Symptoms plus extraintestinal symptoms and
signs n (%) 6 (19.4)
Symptoms plus abnormal imaging n (%) 9 (37)
Symptoms plus inﬂammatory markers n (%) 17 (58.6)
Suggestive endoscopic ﬁndings present n (%) 29 (93.5%)
Erosions/ulcers n (%) 29 (100)
Ulcerated stenosis n (%) 4 (13.7)
Villous atrophy n (%) 3 (10.3)
Duration of follow-up (months) (mean ± SD) 30.7 (13.2)
SD: standard deviation; CRP: C-reactive protein.
the basis of the capsule enteroscopy ﬁndings. We consider
this methodology to be more correct, given the recognised
diﬃcultiesindiagnosingthediseaseandtheabsenceofagold
standard [1].
The issue of selecting patients for SBCE is of the greatest
importance. In fact, the recognition that abdominal pain of
an unknown aetiology should not, on its own, constitute
an indication for capsule enteroscopy [8, 9], as well as
the problem of capsule retention and the high cost of
the procedure, must be taken into consideration. Recently,
the ICCE issued recommendations about SBCE in cases of
suspected CD, formulating an algorithm which proposed
that patients who presented suggestive symptoms plus either
extraintestinal manifestations, inﬂammatory markers, or
abnormal imaging studies should be selected to undergo
capsule enteroscopy [5]. Our results show the high level of
success obtained with the technique when this algorithm
is used. In this context, it is legitimate to ask whether
it would not be preferable, given that the criteria in the
aforementioned algorithm can be met, to opt for balloon-
assisted enteroscopy, thus preventing any capsule retention
and enabling tissue to be collected for biopsy.
A variety of studies have been published seeking to assess
the value of SBCE in the diagnostic assessment of patients
with suspected CD [6, 7, 10–15]. The inclusion criteria,
based on known data relating to the clinical and biological
manifestations of CD, are similar, even though the number
of patients included in each study varies considerably. It
is recognised that, in patients with CD, the endoscopic
ﬁndingsmostfrequentlydetectedbythecapsuleareaphthoid
ulcers/erosions [16]. However, we are far from reaching aDiagnostic and Therapeutic Endoscopy 5
Table 4: Value of diﬀerent criteria in the diagnosis of CD.
Sens. (95%CI) Spec. (95%CI) PPV (95%CI) NPV (95%CI) LLR+ (95%CI) LLR− (95%CI)
Lesions on SBCE 93 (75–98) 80 (64–90) 77 (59–88) 94 (79–99) 4.7 (2.5–8.9) 0.08 (0.02–0.3)
ICCE criteria 65 (45–81) 58 (42–73) 52 (35–69) 70 (52–84) 1.5 (1–2.4) 0.58 (0.34–1)
plus lesions on SBCE 100 (70–100) 86 (64–96) 85 (61–86) 100 (79–100) 7.3 (2.5–20) 0
Symptoms plus extraint.symptoms/signs 24 (11–43) 70 (54–83) 36 (17–61) 56 (42–70) 0.8 (0.3–1.8) 1.0 (0.8–1.34)
plus lesions on SBCE 77 (40–96) 100 (80–100) 100 (50–100) 91 (70–98) (a) 0.22 (0.06–0.7)
Symptoms plus abnormal imaging 29 (13–51) 91 (75–97) 70 (35–91) 65 (50–77) 3.4 (0.9–11) 0.77 (0.59–1)
plus lesions on SBCE 100 (46–100) 96 (80–99) 83 (36–99) 100 (84–100) 29 (4,2–198) 0
Symptoms plus Inﬂammatory markers 55 (35–73) 78 (61–88) 64 (42–81) 71 (55–83) 2.5 (1.2–4.8) 0.57 (0.37–0.8)
plus lesions on SBCE 88 (863–98) 96 (78–99) 94 (69–99) 92 (74–98) 23.1 (3.3–159) 0.1 (0.03–0.4)
Sens.: sensitivity; Spec.: speciﬁcity; PPV: positive predictive value; NPV: negative predictive value; LLR+: likelihood ratio positive; LLR−: likelihood ratio
negative; CI: Conﬁdence Interval; extraint.: extraintestinal; (a)inﬁnity.
Table 5: Endoscopic lesions detected by SBCE in patients with
negative retrograde ileoscopy and subsequent diagnosis of CD.
Negative ileoscopy (N = 43)
CD
conﬁrmed
CD not
conﬁrmed Total
Endoscopic lesions present, n
(%) 21 (87.5) 3 (12.5) 24 (100)
Endoscopic lesions not present,
n (%) 1 (5.3) 18 (94.7) 19 (100)
Total n (%) 22 (51.2) 21 (48.8) 43 (100)
consensus on the number of lesions considered signiﬁcant.
In fact, in the study by Mow et al. [6], the criterion used to
presumeadiagnosis of CD is the presenceof more thanthree
ulcers, whereas in the study by Voderholzer et al. [17] it is the
detection of more than ten aphthoid or erosive lesions. The
question of NSAID is, naturally, crucial, and it is recognised
that NSAID should not be administered to patients involved
in these studies for at least thirty days prior to SBCE [18, 19].
Unlike most of the series cited [6, 7, 11, 14, 15], we did
not exclude patients from our calculations according to the
number of mucosal breaks. In fact, we think that, since there
isnoconsensusonthenumberofmucosalbreaksthatshould
be considered indicative of a diagnosis of CD, the exclusion
of patients on the basis of a numerical criterion appears
arbitrary. It should be emphasised that in our study only
three patients presented three or fewer mucosal breaks. This
data is relevant, given that in the work of Goldstein et al.
[3] no healthy individual without a history of ulcerogenic
medications presented more than three mucosal breaks.
This study highlights the good diagnostic yield of the
technique in patients with suspected CD. In fact, diagnostic
yield achieved 51.3% in our series, which places it within the
range spanning the 37.5% cited in the study by Mow et al.
[6] and the 70.6% of Fireman et al. [10]. These variations
may be related to the diﬀerent admission criteria associated
withNSAIDuse,togetherwiththediﬀerentcharacteristicsof
the patients included in the various studies.
The rate of incomplete enteroscopies, which in our series
was 17.9%, is similar to the rates reported in the literature
considering all the indications [20, 21], consistent with
the hypothesis that CD may not increase the risk of an
incomplete observation [21]. The capsule retention rate in
our series is higher than the one reported in studies which
include all indications [20, 22]. When weighing against
series which include patients with suspected CD, the rate is
also higher, namely, when compared with the rate reported
by Cheifetz et al. [23]a n db yL ie ta l .[ 22], 1.6% and
0%, respectively. It should be noted that for none of our
patients did the clinical assessment and/or the prior imaging
studies suggest the presence of stenosis, and this conforms to
reportsinotherstudieswhichdemonstratethelowreliability
of clinical and imaging studies in predicting the existence
of stenoses [22, 24]. In this context, the recommendation
to carry out imaging studies before capsule enteroscopy
aiming the exclusion of a stenosis [5, 25]i sh a r dt o
understand. In fact, we found that ulcerated stenosis leading
to capsule retention were signiﬁcantly more frequent in the
subgroup of patients with positive inﬂammatory markers.
It should be emphasised that none of our four patients
with retained capsules developed any clinical manifestations
indicative of intestinal occlusion and only two underwent
surgery.
The retrospective nature of our study, along with the
fact that many patients included are referred from other
hospitals, may explain the high rate of unaccomplished
intubations of the terminal ileum. Nevertheless, the question
of ileoscopy in the diagnostic investigation of these patients
also merits discussion. The aim of this study was not to
compare ileoscopy with SBCE, given that patients who
presented lesions indicative of CD in the terminal ileum
did not undergo SBCE. In this context, it was only possible
to calculate the negative predictive value of the ileoscopy
which, as it amounted to 49%, attests to the fact that when
the ileoscopy is negative in these patients, the probability of
existence of the disease is high. Furthermore, the diagnosis
of CD was later established in 22 (51.2%) of the 43 patients
who had a negative ileoscopy, and that in 21 of these SBCE
revealed lesions. The SBCE diagnostic yield for patients with
a negative ileoscopy was 56%, with a high diagnostic acuity,
sensitivity, and negative predictive value for the diagnosis
of CD. The meta-analysis published by Triester et al. [4]6 Diagnostic and Therapeutic Endoscopy
showed that SBCE was not signiﬁcantly better than ileoscopy
for patients with suspected CD. However, a study of double-
balloon enteroscopy demonstrated that, in a high percentage
of patients, ileal involvement in CD may be outside the range
oftheileoscopy[26].Infact,themostrecentpublishedmeta-
analysis by Dionisio et al. shows that SBCE is superior to
colonoscopywithileoscopy[27].Ourresultscorroboratethis
ﬁnding, signifying that, faced with clinically suspected CD
andanegativeileoscopy,theuseofenteroscopy,namely,with
capsule, is advisable.
In conclusion, SBCE is a valid diagnostic tool in patients
with suspected CD, namely, when inﬂammatory markers
are present. It is particularly informative when lesions are
not detected, a case in which the diagnosis of CD is very
unlikely. The use of SBCE in this indication may lead to
retention of the capsule, more frequently in the subgroup of
patients with positive inﬂammatory markers, but this event
is not accompanied by symptoms of intestinal occlusion
and can be remedied without the need for surgery. Finally,
the diagnosis of CD is not infrequent among patients with
negative ileoscopy, suggesting that capsule enteroscopy is
advisable in these cases.
References
[1] E. F. Stange, S. P. L. Travis, S. Vermeire et al., “European
evidence based consensus on the diagnosis and management
of Crohn’s disease: deﬁnitions and diagnosis,” Gut, vol. 55, no.
1, pp. i1–i15, 2006.
[2] A. Bourreille, A. Ignjatovic, L. Aabakken et al., “Role of
small-bowel endoscopy in the management of patients with
inﬂammatory bowel disease: an international OMED-ECCO
consensus,” Endoscopy, vol. 41, no. 7, pp. 618–637, 2009.
[3] J. L. Goldstein, G. M. Eisen, B. Lewis, I. M. Gralnek, S.
Zlotnick,andJ.G.Fort,“Videocapsuleendoscopytoprospec-
tively assess small bowel injury with celecoxib, naproxen
plus omeprazole, and placebo,” Clinical Gastroenterology and
Hepatology, vol. 3, no. 2, pp. 133–141, 2005.
[4] S. L. Triester, J. A. Leighton, G. I. Leontiadis et al., “A meta-
analysis of the yield of capsule endoscopy compared to other
diagnostic modalities in patients with non-stricturing small
bowel Crohn’s disease,” American Journal of Gastroenterology,
vol. 101, no. 5, pp. 954–964, 2006.
[5] K. Mergener, T. Ponchon, I. Gralnek et al., “Literature
review and recommendations for clinical application of small-
bowel capsule endoscopy, based on a panel discussion by
international experts,” Endoscopy, vol. 39, no. 10, pp. 895–909,
2007.
[6] W. S.Mow,S.K.Lo,S.R.Targan etal.,“Initialexperience with
wirelesscapsuleenteroscopyinthediagnosisandmanagement
of inﬂammatory bowel disease,” Clinical Gastroenterology and
Hepatology, vol. 2, no. 1, pp. 31–40, 2004.
[7] M. Tukey, D. Pleskow, P. Legnani, A. S. Cheifetz, and A. C.
Moss, “The utility of capsule endoscopy in patients with sus-
pected Crohn’s disease,” American Journal of Gastroenterology,
vol. 104, pp. 2734–2739, 2009.
[8] E. Bardan, M. Nadler, Y. Chowers, H. Fidder, and S. Bar-
Meir, “Capsule endoscopy for the evaluation of patients with
chronic abdominal pain,” Endoscopy, vol. 35, no. 8, pp. 688–
689, 2003.
[ 9 ]L .C .F r y ,E .J .C a r e y ,A .D .S h i ﬀ et al., “The yield of capsule
endoscopy in patients with abdominal pain or diarrhea,”
Endoscopy, vol. 38, no. 5, pp. 498–502, 2006.
[10] Z. Fireman, E. Mahajna, E. Broide et al., “Diagnosing small
bowel Crohn’s disease with wireless capsule endoscopy,” Gut,
vol. 52, no. 3, pp. 390–392, 2003.
[11] M. De Bona, A. Bellumat, E. Cian, F. Valiante, A. Moschini,
and M. De Boni, “Capsule endoscopy ﬁndings in patients
with suspected Crohn’s disease and biochemical markers of
inﬂammation,” Digestive and Liver Disease,v o l .3 8 ,n o .5 ,p p .
331–335, 2006.
[12] Z.-Z. Ge, Y.-B. Hu, and S.-D. Xiao, “Capsule endoscopy in
diagnosis of small bowel Crohn’s disease,” World Journal of
Gastroenterology, vol. 10, no. 9, pp. 1349–1352, 2004.
[13] J. M. Herrer´ ıas, A. Caunedo, M. Rodr´ ıguez-T´ ellez, F. Pellicer,
and J. M. Herrer´ ıas Jr., “Capsule endoscopy in patients with
suspectedCrohn’sdiseaseandnegativeendoscopy,”Endoscopy,
vol. 35, no. 7, pp. 564–568, 2003.
[14] C. M. Girelli, P. Porta, V. Malacrida, F. Barzaghi, and F. Rocca,
“Clinical outcome of patients examined by capsule endoscopy
for suspected small bowel Crohn’s disease,” Digestive and Liver
Disease, vol. 39, no. 2, pp. 148–154, 2007.
[15] J. Valle, M. Alc´ antara, M. J. P´ erez-Grueso et al., “Clinical
features of patients with negative results from traditional
diagnostic work-up and Crohn’s disease ﬁndings from capsule
endoscopy,” Journal of Clinical Gastroenterology, vol. 40, no. 8,
pp. 692–696, 2006.
[ 1 6 ]A .K o r n b l u t h ,J .F .C o l o m b e l ,J .A .L e i g h t o n ,a n dE .L o f t u s ,
“ICCE consensus for inﬂammatory bowel disease,” Endoscopy,
vol. 37, no. 10, pp. 1051–1054, 2005.
[17] W. A. Voderholzer, J. Beinhoelzl, P. Rogalla et al., “Small bowel
involvement in Crohn’s disease: a prospective comparison
of wireless capsule endoscopy and computed tomography
enteroclysis,” Gut, vol. 54, no. 3, pp. 369–373, 2005.
[18] L.Maiden,B.Thjodleifsson,A.Seigaletal.,“Long-termeﬀects
of nonsteroidal anti-inﬂammatory drugs and cyclooxygenase-
2 selective agents on the small bowel: a cross-sectional capsule
enteroscopy study,” Clinical Gastroenterology and Hepatology,
vol. 5, no. 9, pp. 1040–1045, 2007.
[19] L. Maiden, B. Thjodleifsson, A. Theodors, J. Gonzalez, and I.
Bjarnason, “A quantitative analysis of NSAID-induced small
bowel pathology by capsule enteroscopy,” Gastroenterology,
vol. 128, no. 5, pp. 1172–1178, 2005.
[20] E. Rondonotti, J. M. Herrerias, M. Pennazio, A. Caunedo,
M.Mascarenhas-Saraiva,andR.DeFranchis,“Complications,
limitations, and failures of capsule endoscopy: a review of 733
cases,” Gastrointestinal Endoscopy, vol. 62, no. 5, pp. 712–716,
2005.
[21] J. Westerhof, R. K. Weersma, and J. J. Koornstra, “Risk factors
for incomplete small-bowel capsule endoscopy,” Gastrointesti-
nal Endoscopy, vol. 69, no. 1, pp. 74–80, 2009.
[22] F. Li, S. R. Gurudu, G. De Petris et al., “Retention of the
capsule endoscope: a single-center experience of 1000 capsule
endoscopy procedures,” Gastrointestinal Endoscopy, vol. 68,
no. 1, pp. 174–180, 2008.
[23] A. S. Cheifetz, A. A. Kornbluth, P. Legnani et al., “The
risk of retention of the capsule endoscope in patients with
known or suspected Crohn’s disease,” American Journal of
Gastroenterology, vol. 101, no. 10, pp. 2218–2222, 2006.
[24] A. S. Cheifetz and B. S. Lewis, “Capsule endoscopy retention:
is it a complication?” Journal of Clinical Gastroenterology, vol.
40, no. 8, pp. 688–691, 2006.Diagnostic and Therapeutic Endoscopy 7
[25] G. R. Lichtenstein, S. B. Hanauer, W. J. Sandborn et al.,
“Management of Crohn’s disease in adults,” American Journal
of Gastroenterology, vol. 104, no. 2, pp. 465–483, 2009.
[26] N. Oshitani, T. Yukawa, H. Yamagami et al., “Evaluation of
deep small bowel involvement by double-balloon enteroscopy
in Crohn’s disease,” American Journal of Gastroenterology, vol.
101, no. 7, pp. 1484–1489, 2006.
[27] P. M. Dionisio, S. R. Gurudu, J. A. Leighton et al., “Capsule
endoscopy has a signiﬁcantly higher diagnostic yield in
patients with suspected and established small-bowel Crohn’s
disease: a meta-analysis,” American Journal of Gastroenterol-
ogy, vol. 105, no. 6, pp. 1240–1248, 2010.